# US 2024/0002859 A1 · Pmo-based utrophin::let-7c mirna site blocking oligonucleotides (sbos) for treating duchenne muscular dystrophy (dmd)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002859 A1
- Document ID: US20240002859A1
- Status: Published application
- Kind: A1
- Application number: 18/253,919
- Filed: 2021-11-22
- Published: 2024-01-04
- Earliest claimed: 2020-11-23
- Assignees: The Trustees of the University of Pennsylvania
- Applicants: The Trustees of the University of Pennsylvania
- Inventors: Tejvir S. S. KHURANA
- Web page: https://patentgrep.com/patent/US20240002859A1

## CPC

- C12N 15/1138: {against receptors or cell surface proteins}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2310/314: Phosphoramidates
- C12N 2310/3233: Morpholino-type ring
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides methods and compositions for enhancing utrophin protein production by inhibiting binding of a Let-7c microRNA molecule to its binding site in the utrophin mRNA 3′-untranslated region (UTR). In particular, phosphorodiamidate morpholino oligonucleotide (PMO) site blocking oligonucleotides (SBOs) that inhibit Let-7c miRNA binding to its binding site in the utrophin mRNA 3′UTR. Moreover. methods of enhancing utrophin protein production in muscle cells can be used to treat muscular dystrophy and/or other myopathies.

## Claims

### Claim 1

A method of treating Duchenne Muscular Dystrophy (DMD) in a human subject, the method comprising administering to said subject an effective amount of an oligonucleotide that (i) specifically hybridizes to a Let-7e microRNA binding sequence in a utrophin mRNA 3′-untranslated region (UTR) and (ii) inhibits binding of a Let-7c microRNA to the utrophin mRNA 3′-UTR.

### Claim 2 (depends on 1)

The method of claim 1, wherein the oligonucleotide comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-5.

### Claim 3 (depends on 1)

The method of claim 1, wherein the oligonucleotide has a sequence comprising SEQ ID NO: 5.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the oligonucleotide is a morpholino or phosphorodiamidate morpholino (PMO) oligonucleotide.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the oligonucleotide is between 24 and 29 nucleotides long.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method any one of claims 1-5, wherein the oligonucleotide is administered systemically.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The method any one of claims 1-5, wherein the oligonucleotide is administered intramuscularly.

### Claim 8 (depends on 1)

The method of claim 1, further comprising the step of administering to said subject an effective amount of a second oligonucleotide that (i) specifically hybridizes to a second microRNA binding sequence in the utrophin mRNA 3′-UTR and (ii) inhibits binding of the second microRNA to the utrophin mRNA 3′-UTR, wherein said second microRNA is selected from the group consisting of miR-133b, miR-150, miR-196b, miR-206, and miR-296-5p.

### Claim 9

A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and an oligonucleotide that specifically hybridizes to a Let-7c microRNA binding sequence in a utrophin mRNA 3′-untranslated region (UTR), wherein the oligonucleotide is present in an amount effective in a human subject to inhibit binding of Let-7 microRNA to its utrophin mRNA 3′-UTR.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the oligonucleotide comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-5.

### Claim 11 (depends on 9)

The composition of claim 9, wherein the oligonucleotide has a sequence comprising SEQ ID NO: 5.

### Claim 12 (depends on 9, 10, 11)

The composition of any one of claims 9-11, wherein the oligonucleotide is a morpholino or phosphorodiamidate morpholino (PMO) oligonucleotide.

### Claim 13 (depends on 9, 10, 11, 12)

The composition of any one of claims 9-12, wherein the oligonucleotide is between 24 and 29 nucleotides long.

### Claim 14 (depends on 9, 10, 11, 12, 13)

The composition of any one of claims 9-13, wherein the composition is formulated for systemic administration to a subject.

### Claim 15 (depends on 9, 10, 11, 12, 13)

The composition of any one of claims 9-13, wherein the composition is formulated for intramuscular administration to a subject.

### Claim 16 (depends on 9)

The composition of claim 9, further comprising at least one additional oligonucleotide that specifically hybridizes to at least one additional microRNA binding sequence in the utrophin mRNA 3′-UTR, wherein the additional microRNA is selected from the group consisting of miR-133b, miR-150, miR-196b, miR-206, and miR-296-Sp, and wherein the additional oligonucleotide is present in an amount effective in a human subject to inhibit binding of the additional microRNA to its corresponding utrophin mRNA 3′-UTR binding sequence.

### Claim 17

A method for enhancing utrophin production in a subject, the method comprising administering to said subject an oligonucleotide that (i) specifically hybridizes to a Let-7c microRNA binding sequence in a utrophin mRNA 3′-untranslated region (UTR) and (ii) inhibits binding of a Let-7c microRNA to the utrophin mRNA 3′-UTR.

### Claim 18 (depends on 17)

The method of claim 17, wherein the oligonucleotide comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 1-5.

### Claim 19 (depends on 17, 18)

The method of claim 17 or claim 18, wherein the oligonucleotide is a morpholino or phosphorodiamidate morpholino (PMO) oligonucleotide.
